Genzyme to start shipping Fabrazyme from newly-approved plant

1 March 2012

French drug major Sanofi’s (Euronext: SAN) US subsidiary Genzyme says that it has begun shipping its Fabry disease drug Fabrazyme (agalsidase beta) produced at its newly-approved plant in Framingham, Massachusetts. Sanofi’s shares moved 1.9% higher to 56.55 euros by early afternoon trading yesterday.

As previously communicated, patients in the USA are now able to return to full dosing in March. In addition, all new patients in the US are eligible to begin Fabrazyme treatment, at full dosing levels.

“The ability to meet the needs of patients in the USA is an important first step in restoring unconstrained supply for all patients globally throughout the course of 2012,” said Genzyme’s president and chief executive David Meeker.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK